The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma - Episode 11

Pioneering Breakthroughs in HCC Treatment

In their concluding remarks, Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, express their hopes for future advancements in hepatocellular carcinoma (HCC) treatment, including cellular-based therapies, antibody-drug conjugates, and an increased focus on neoadjuvant studies.